TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 172 filers reported holding TRAVERE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.45 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,168,779 | -41.3% | 690,020 | +0.9% | 0.00% | -50.0% |
| Q2 2023 | $10,508,283 | -32.4% | 684,133 | -1.0% | 0.00% | -33.3% |
| Q1 2023 | $15,538,363 | +16.0% | 690,901 | +8.5% | 0.00% | 0.0% |
| Q4 2022 | $13,390,326 | -14.0% | 636,725 | +0.7% | 0.00% | -25.0% |
| Q3 2022 | $15,576,000 | +1.0% | 632,145 | -0.7% | 0.00% | +33.3% |
| Q2 2022 | $15,422,000 | -4.4% | 636,514 | +1.6% | 0.00% | 0.0% |
| Q1 2022 | $16,139,000 | -6.5% | 626,260 | +12.7% | 0.00% | 0.0% |
| Q4 2021 | $17,252,000 | +26.9% | 555,796 | -0.9% | 0.00% | +50.0% |
| Q3 2021 | $13,595,000 | +50.6% | 560,615 | -9.4% | 0.00% | 0.0% |
| Q2 2021 | $9,028,000 | -43.6% | 618,745 | -3.5% | 0.00% | -33.3% |
| Q1 2021 | $16,004,000 | -4.5% | 640,921 | +4.2% | 0.00% | 0.0% |
| Q4 2020 | $16,758,000 | – | 614,897 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 895,821 | $8,008,640 | 3.99% |
| Deep Track Capital, LP | 7,370,000 | $65,887,800 | 2.54% |
| VR Adviser, LLC | 2,623,677 | $23,455,672 | 2.47% |
| Sio Capital Management, LLC | 884,770 | $7,909,844 | 2.45% |
| Kynam Capital Management, LP | 957,502 | $8,560,068 | 1.40% |
| MPM BioImpact LLC | 552,846 | $4,942,443 | 1.32% |
| ARMISTICE CAPITAL, LLC | 7,500,000 | $67,050,000 | 1.03% |
| Parkman Healthcare Partners LLC | 577,494 | $5,162,796 | 0.95% |
| Tri Locum Partners LP | 251,702 | $2,250,216 | 0.72% |
| Cheyne Capital Management (UK) LLP | 26,200 | $234,228 | 0.68% |